CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Empagliflozin

Last Updated: May 23, 2018
Result type: Reports
Project Number: SR0427-000
Product Line: Reimbursement Review

Generic Name: Empagliflozin

Brand Name: Jardiance

Manufacturer: Boehringer Ingelheim (Canada) Ltd.

Therapeutic Area: Diabetes mellitus, type 2

Indications: Diabetes mellitus (Type 2)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: October 15, 2015

Recommendation Type: List with clinical criteria and/or conditions